去甲斑蝥酸钠联合肝动脉栓塞化疗术治疗中晚期肝癌的临床研究

摘要

目的 观察去甲斑蝥酸钠(SNCTD)联合肝动脉栓塞化疗(TACE)术治疗中晚期肝癌的临床疗效及不良反应.方法 选取我院2006年1月至2009年2月收治的128例原发性肝癌患者,随机分为治疗组(SNCTD联合TACE)64例与对照组(单纯TACE)64例,观察两组近期疗效、前3年生存率、治疗前后生活质量卡氏评分(KPS)及不良反应.结果 治疗组与对照组治疗前后近期总有效率分别为82.81%、56.25%,治疗组前3年生存率分别为78.13%、65.63%、34.38%.对照组前3年生存率分别为46.88%、32.81%、14.06%,外周血象、生活质量KPS评分值均比治疗前有不同程度的提高,两组间差异均有统计学意义(P＜0.05).结论 SNCTD联合TACE术治疗中晚期肝癌能协同增效,对延长患者的生存时间,改善患者生活质量,降低粒细胞减少的发生方面有一定的临床价值.%Objective To evaluate the clinical efficacy and side effects of the treatment of advanced liver cancer by sodium norcantharidin( SNCTD )combined with transcatheter hepatic arterial chemoembolization( TACE ). Methods 128 patients with primary liver cancer were randomly divided into two groups: one group of 64patients received the treatment of SNCTD combined with TACE and the other 64 patients received the treatment of TACE. The term effect,3-year survival, the chang of quality of life and adverse effect before and after treatment( KPS score )of the two groups were observed. Results The short-term total effective rate of the treatment group and the control group was 82.81％ and 56.25％ respectively; 3-year survival rate by year of the treatment group was 78.13％ ,65.63％ ,34.38％ respectively; 3-year survival rate by year of the control group was 46.88％ ,32.81％ ,14.06％ respectively. After treatment improvement in peripheral blood and life quality ( KPS score )of different degrees were observed with significant difference between the two groups( P ＜ 0.05 ).Conclusion The treatment for advanced liver cancer by SNCTD combined TACE is synergistic; a certain clinical value is seen in the aspect of extending survival time,improving life quality and reducing the incidence of neutropenia.